Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-15
2008-04-15
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
11130295
ABSTRACT:
This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms using the farnesylated dibenzodiazepinone compound of Formula I. The invention includes pharmaceutical compositions comprising the compound of Formula I:
REFERENCES:
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4452775 (1984-06-01), Kent
patent: 5039660 (1991-08-01), Leonard
patent: 5541181 (1996-07-01), Ohkuma et al.
patent: 2003/0109518 (2003-06-01), Lu et al.
patent: 2003/0219718 (2003-11-01), Weber et al.
patent: 2004/0220179 (2004-11-01), Lu et al.
patent: 2248820 (1997-09-01), None
Igarashi, et al., “Revision of the Structure Assigned to the Antibiotic BU-4664L fromMicromonopora”, Journal of Antibiotics (2005), V. 58, No. 7, pp. 350-352.
Correction to p. 352. Igarashi, et al., “Revision of the Structure Assigned to the Antibiotic BU-4664L fromMicromonopora”, Journal of Antibiotics (2005), V. 58, No. 7, pp. 350-352.
Charan, et al., “A New Antimicrobial Alkaloid from aMicromonosporasp.”, Abstract and Figures from Poster Presentation #p:157 at the 44thAnnual Meeting of the American Society of Pharmacognosy, Chapel Hill, N.C., Jul. 12-16, 2003.
Embley and Stackebrandt, “The molecular phylogeny and systematics of the actinomycetes”, Annual Review Microbiology (1994), V. 48, pp. 257-289.
British Journal of Cancer (1998) vol. 77(1) pp. 1-11 United Kingdom Co-ordinating Committee on Cancer Reseach (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).
Charan et al., “Diazepinomicin, a new antimicrobial alkaloid from a marineMicromonosporasp”, Journal of Nat Prod. Aug. 2004, 67(8), pp. 1431-1433.
Alberts, et al., Molecular Biology of the Cell (3rdedition), Garland Publishing, Inc (1994) pp. 1255-1294.
Alberts B. et al., Molecular Biology of the Cell (3d ed. 1994) pp. 1255-1294.
Berge S. et al., Journal of Pharmaceutical Sciences (1977) vol. 66, No. 1, pp. 1-19 “Pharmaceuticals Salts”.
Rooseboom M. et al., Pharmacol. Reviews (2004), vol. 56, pp. 53-102 “Enzyme-Catalyzed Activiation of Anticancer Prodrugs”.
Goodfellow M., Bergey's Manual of Systematic Bacteriology (1989) vol. 4, pp. 2333-2339 “Suprageneric Classification of Actinomycetes”.
Embley and Stackebrandt, Annu. Rev. Microbiol. (1994) vol. 48, pp. 257-289 “The molecular phylogeny and systematics of the actinomycetes”.
Carayon P. et al., Blood (1996 vol. 87, No. 8, pp. 3170-3178 “Involvement of Peripheral Benzodiazepine Receptors in the Protection of Hematopoietic Cells Against Oxygen Radical Damage”.
Hirsch T. et al., Experimental Cell Research (1998) vol. 241, No. 2, pp. 426-434 “PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection”.
Bono F. et al., Biochem. Biophys. Res. Comm. (1999) vol. 265, No. 2, pp. 457-461 “Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities”.
Miettinen H. et al., Cancer Res. (1995) vol. 55, No. 12, pp. 2691-2695 “Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation”.
Katz Y. et al., Clin Sci. (1990) vol. 78, No. 2, pp. 155-158 “Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumours and normal ovaries”.
Katz Y. et al., Oncology (1990) vol. 47, No. 2, pp. 139-142 “Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma”.
Venturini I. et al., Life Sci. (1999) vol. 65, No. 21, pp. 2223-2231 “Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver”.
Verma A. et al., Mol. Med. (1998) vol. 4, No. 1, pp. 40-45 “Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target”.
Kupczyk-Subotkowska L. et al., J. Med. Chem. (1997) vol. 40, No. 11, pp. 1726-1730 “Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate”.
Guo P. et al., Cancer Chemother. Pharmacol. (2001) vol. 48, No. 2, pp. 169-176 “Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model”.
Wang J. et al., Prod. Natl. Acad. Sci. USA (1984) vol. 81, pp. 753-756 “Benzodiazepines that bind at peripheral sites inhibit cell proliferation”.
LandauM. et al., J. Biochem. Pharmacol. (1998) vol. 56, No. 8, pp. 1029-1034 “Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 meanoma cells”.
Stoebner PE et al., Cell Death Differ. (2001) vol. 8, No. 7, pp. 747-753 “Transient protection by peripheral benzodiazepine receptors during the early events of ultraviolet light-induced apoptosis”.
Jakubikova J. et al., Neoplasma (2002) vol. 49, No. 4, pp. 231-236 “PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro”.
Decaudin D. et al., Cancer Res. (2002) vol. 62, No. 5, pp. 1388-1393 “Peripheral Benzodiazepine Receptor Ligands Reverse Apoptosis Resistance of Cancer Cells in Vitro and in Vivo”.
Childs S., Imp. Adv. Oncol. (1994) pp. 21-36 “The MDR superfamily of genes and its biological implications”.
Fan D. et al., Reversal of Multidrug Resistance in Cancer, ed. Kellen, J.A. (1993) pp. 93-125.
Cole S.P.C. et al., Science (1992) vol. 258, pp. 1650-1654 “Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line”.
Scheffer G.L. et al., Nat. Med. (1995) vol. 1, No. 6, pp. 578-582 “The drug resistance-related protein LRP is the human major vault protein”.
Beck W.T., J. Natl., Cancer Inst. (1989) vol. 81, No. 22, pp. 1683-1685 “Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance”.
Freireich EJ. et al., Cancer Chemother. Reports (1966) vol. 50, No. 4, pp. 219-244 “Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man”.
Workman et al., British Journal of Cancer (1998) vol. 77, pp. 1-10 United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).
Premont J. et al., Biochim Biophys Acta. (1975) vol. 381, No. 2, pp. 368-376 “[3H] norepinephrine binding by rat glial cells in culture. Lack of correlation between binding and adenylate cyclase activation”.
Le Fur G. et al., Life Sci. USA (1983) vol. 33, No. 5, pp. 449-457 “Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies”.
Damm HW et al., Res. Comm. Chem. Pathol. Pharmacol. (1978) vol. 22, pp. 597-600′ [3H] Flunitrazepam: its advantages as a ligand for the identification of benzodiazepine receptors in rat brain membranes.
Speth RC. et al., Life Sci. (1979) vol. 24, No. 4, pp. 351-357 “Benzodiazepine receptors: temperature dependence of [H3] flunitrazepam binding”.
De George JJ. et als., Cancer Chemother. Pharmacol. (1998) vol. 41, pp. 173-185 “Regulatory considerations for preclinical development of anticancer drugs”.
Lash L, Toxicological Sciences (2003) vol. 74, pp. 1-3 “The mitochondrial benzodiazepine receptor as a potential target protein for drug development: Demonstration of functional significance with cell lines exhibiting differntial expression of Bcl-2”.
Pawlikowski M. et al., Acta Neurol. Scand. (1988) pp. 231-233 “Inhibition of cell proliferation
Berger Francois
Dimitriadou Violetta
Falardeau Pierre
Farnet Chris M.
Gourdeau Henriette
Kifle Bruck
Thallion Pharmaceuticals Inc.
LandOfFree
Compositions and methods comprising farnesyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods comprising farnesyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods comprising farnesyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3924912